Cargando…
Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up
PURPOSE: To evaluate the efficacy of concurrent chemoradiotherapy (CCRT) in subgroups of stage III nasopharyngeal carcinoma (NPC) in the context of intensity-modulated radiotherapy (IMRT). METHODS: A total of 272 patients with stage III NPC who underwent IMRT with or without concurrent chemotherapy...
Autores principales: | Wang, Lei, Wu, Zheng, Cheng, Wanqin, Xie, Dehuan, Lin, Feifei, Xia, Liangping, Su, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571837/ https://www.ncbi.nlm.nih.gov/pubmed/34742304 http://dx.doi.org/10.1186/s13014-021-01929-9 |
Ejemplares similares
-
Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis
por: Wang, Lei, et al.
Publicado: (2020) -
Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma
por: Chen, Jing, et al.
Publicado: (2020) -
Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study
por: Yin, Yuanxiu, et al.
Publicado: (2022) -
Clinical outcomes of non‐nasopharyngeal lymphoepithelial carcinoma treated with a combined modality approach: A single‐institution study
por: Qiu, Zichen, et al.
Publicado: (2022) -
Efficacy of concurrent chemoradiotherapy combined with nimotuzumab for low-risk T4 stage nasopharyngeal carcinoma: A pilot study
por: Zhang, Shuai, et al.
Publicado: (2018)